
Opinion|Videos|January 6, 2026
Navigating Bridging Therapy With CAR T-Cell Therapy in Multiple Myeloma
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss considerations for bridging therapy ahead of CAR T-cell therapy in multiple myeloma.
Advertisement
Episodes in this series

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss key considerations when selecting and managing bridging therapy prior to CAR T-cell infusion in multiple myeloma. They examine how disease burden, prior treatments, and manufacturing timelines influence bridging strategy choices. Merz and Bellerive emphasize balancing disease control with preservation of T-cell fitness ahead of infusion.
Advertisement
Related to this article

The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.

Phase 2 NB2012 data showed a 3-year event-free survival rate of 73.7% with daretabart plus induction chemotherapy.

Deepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.

Mayo Clinic researchers identified BRCA2 variants linked to moderate breast cancer risk, potentially informing personalized screening and prevention.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
3
Galinpepimut-S Improves OS in AML in Second or Later Remission
4
ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC
5

